8-K: Turn Therapeutics Updates GX-03 Phase 2 Program for Atopic Dermatitis

Turn Therapeutics announced an updated Stage 2 design for its Phase 2 program of GX-03 in atopic dermatitis, incorporating interim analysis data to broaden patient evaluation across all disease severities.

Summary

• Turn Therapeutics has completed a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial for GX-03 in treating atopic dermatitis.
• This analysis has led to a refined Stage 2 study design, optimizing patient selection, disease stratification, endpoint evaluation, and statistical methodology.
• The company observed clinically meaningful efficacy across a wider range of atopic dermatitis severity than initially anticipated.
• The Phase 2 program will now prospectively evaluate patients across the full spectrum of disease severity, as measured by the Eczema Area and Severity Index (EASI).
• The final Stage 2 design will utilize the FDA-recognized Hochberg multiple testing procedure to establish statistical significance across multiple efficacy endpoints.
• Enrollment has continued uninterrupted, and patients enrolled during the review period will be included in the final Stage 2 design.
• The company anticipates completing enrollment in the fourth quarter of 2026 and expects topline results in the same quarter.
• Turn Therapeutics stated it is sufficiently capitalized to support the completion of the study and operations through the third quarter of 2027.
• A webcast was scheduled for July 7, 2026, at 4:30 p.m. Eastern Time to discuss these updates.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the data-driven refinement of the trial design and observed efficacy in a broader patient population, although the negative treatment difference in one specific subgroup metric warrants attention.

Positives

• Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis severity than originally anticipated.
• The Stage 2 design has been optimized based on data-driven refinements, increasing the probability of success.
• GX-03 demonstrated clinically meaningful efficacy in patients with baseline EASI scores of 1.1 to 7.0 (mild-to-moderate disease).
• GX-03 showed improvements in Week 4 vIGA-AD Success and Week 4/Week 8 EASI-100 within the mild-to-moderate subgroup.
• The drug continues to demonstrate a favorable safety and tolerability profile with no treatment-related serious adverse events reported.
• The company is sufficiently capitalized to support study completion and operations through Q3 2027.
• The adaptive trial design allows for learning from Stage 1 to strengthen Stage 2, optimizing resource use and providing flexibility.

Negatives

• While efficacy was observed in mild-to-moderate patients (EASI 1.1-7.0), the data presented for this subgroup shows a negative treatment difference for Week 8 EASI-100 (-5.6%) compared to vehicle, though other endpoints in this subgroup were positive.
• The presentation notes that baseline characteristics favored the vehicle group in the EASI 1.1-7.0 subgroup analysis, which could complicate interpretation.
• The presentation also notes that baseline characteristics favored the vehicle group in the representative Stage 2 subgroup (EASI >= 1.1 and PP-NRS >= 7) for Week 8 EASI-100 (-37.9% treatment difference).

Risks

• Risks related to the success of development programs, availability of additional financing, and the company's ability to execute its strategic plan.
• Uncertainties in clinical development and obtaining regulatory approvals.
• No guarantee that pipeline products will prove commercially successful.
• Reliance on third-party partnerships and manufacturers.
• Dependence on patent protections.
• The company undertakes no obligation to update forward-looking statements, which means future developments may not be reflected.
• Cross-trial comparisons of efficacy data are for illustrative purposes only and cannot be made due to differences in trial design and patient populations.

Future Outlook

Turn Therapeutics anticipates completing enrollment in the Stage 2 trial during the fourth quarter of 2026 and expects to report topline results in the same quarter. The company also anticipates a Type-B meeting with the FDA in Q4 2026 and potentially initiating Phase 3 trials in the first half of 2027, subject to successful completion of prior phases and capital availability. The company is sufficiently capitalized to support study completion and planned operations through the third quarter of 2027.

Management Comments

• "The purpose of a staged, adaptive clinical trial is to learn from the first stage to strengthen the second. GX-03 demonstrated meaningful activity across a wider spectrum of atopic dermatitis severity than we originally anticipated. We believe the optimized Stage 2 design strengthens the current study while generating data that could support broader development and future labeling opportunities for GX-03."
• "GX-03 demonstrated meaningful activity across a wider spectrum of atopic dermatitis severity than we originally anticipated."

Industry Context

StockSavvy.ai notes that Turn Therapeutics' update on GX-03 positions it within the competitive landscape of atopic dermatitis treatments, a significant and growing market. The company's strategy to broaden patient evaluation and refine its trial design reflects industry trends towards more precise patient stratification and robust statistical methodologies to navigate complex regulatory pathways.

Comparison to Industry Standards

• The presentation includes comparisons of GX-03's interim efficacy data against FDA-approved topical Atopic Dermatitis (AD) drugs (Zoryve, Eucrisa, Vtama, Opzelura) and clinical-stage biologics (Zumilokibart, Dupixent, Ebglyss, Nemluvio, Adbry).
• For Week 4 vIGA-AD Success, GX-03's interim subgroup (EASI 1.1-7.0) showed 71.4% success, which is higher than Zoryve (25%), Eucrisa (~4 weeks equivalent), and Vtama (not directly comparable due to Week 8 endpoint).
• For Week 4 EASI-100, GX-03's interim subgroup showed 28.6% success, compared to Zoryve (25%) and Eucrisa (not directly comparable).
• For Week 8 EASI-100, GX-03's interim subgroup showed 35.7% success, compared to Vtama (not directly comparable due to Week 8 endpoint), Opzelura (not directly comparable due to Week 8 endpoint), and Anzupgo (not directly comparable).
• The presentation cautions that these are cross-trial comparisons and not head-to-head, with differences in trial design, patient populations, and statistical treatments of missing data.
• In the representative Stage 2 subgroup (EASI >= 1.1 and PP-NRS >= 7), GX-03 showed Week 4 vIGA-AD Success of 61.5%, Week 4 EASI-75 of 69.2%, Week 8 EASI-90 of 53.8%, and Week 8 EASI-100 of 46.2%. These figures are presented alongside data from other approved therapies, but direct comparison is limited.

Stakeholder Impact

• Shareholders: The update provides clarity on the GX-03 development path and timeline, potentially impacting investment decisions. The company's stated capitalization provides some assurance regarding ongoing operations.
• Patients: The expansion of the trial to include a broader spectrum of atopic dermatitis severity could lead to a treatment option for a wider patient population if GX-03 is successful.
• Healthcare Providers: The refined study design and potential for a new treatment option will be of interest to dermatologists and other healthcare professionals treating atopic dermatitis.

Next Steps

• Continue enrollment under the final Stage 2 protocol.
• Complete enrollment during the fourth quarter of 2026.
• Report topline results from Stage 2 in the fourth quarter of 2026.
• Hold a Type-B meeting with the FDA in Q4 2026.
• Initiate Phase 3 trials in the first half of 2027 (subject to successful completion of each phase and capital availability).

Key Dates

Recommendation

The update provides positive progress on the GX-03 Phase 2 trial with a refined design and observed efficacy. However, the company is still in clinical development, and the path to commercialization involves significant risks and requires further capital. The current information supports a 'hold' recommendation, pending further data and regulatory milestones.

Keywords

Turn Therapeutics, GX-03, Atopic Dermatitis, Phase 2 Trial, Clinical Development, Biotechnology, Eczema Area and Severity Index, EASI, Validated Investigator Global Assessment, vIGA-AD, Hochberg Procedure, Inflammatory Skin Diseases, TTRX